Les carcinomes du nasopharynx

Données actuelles

Translated title of the contribution: Nasopharyngeal carcinoma. Recent data

H. Boussen, N. Bouaouina, N. Mokni-Baizig, A. Gamoudi, Lotfi Chouchane, F. Benna, A. Ladgham

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Nasopharyngeal carcinoma (NPC) represents an interesting model in the field of head and neck cancers. This cancer is rare in occidental countries (<1/100,000) and relatively moderate to highly frequent in the Mediterranean area and south-east Asia. This disease is linked to Epstein-Barr virus with a latent infection starting in the oropharyngeal epithelium and involving not only both epithelial tumor cells but also B lymphocytes. This viral infection represents the early phase of carcinogenesis where Latent Membrane Protein-1 has an important role via the terminal part of the BARF-1 gene. There are also various chromosomal alterations reported in NPC concerning the regions of chromosomes 3p, 9p, 11q, 13q, 14q et 16q detected essentially in areas of suppressors genes. Allelic and antigenic specificities of class II and II HLA seems to be associated to an increased risk of NPC different according to the incidence areas. Anti-EBV serology is suggestive of for NPC with an elevated level of IgA EA (early antigen) and VCA (viral capsid antigen). Cyfra 21 represents a promising serum marker for NPC with a 80% sensitivity. Radiotherapy remains the base of loco-regional treatment with a more frequent and systematic use of systemic chemotherapy (primary or concomitant) for high-risk-patients (T3-4 and N2-3 disease).

Original languageFrench
Pages (from-to)45-51
Number of pages7
JournalPathologie Biologie
Volume53
Issue number1
DOIs
Publication statusPublished - Jan 2005
Externally publishedYes

Fingerprint

Genes
Chemotherapy
Lymphocytes
Viral Antigens
Radiotherapy
Chromosomes
Viruses
Immunoglobulin A
Tumors
Epitopes
Membrane Proteins
Human Herpesvirus 4
Cells
Antigens
Suppressor Genes
Far East
Capsid
Virus Diseases
Serology
Head and Neck Neoplasms

Keywords

  • Carcinoma
  • Carcinome
  • Chimiothérapie
  • Epstein-Barr
  • Epstein-Barr virus
  • Gène suppresseur
  • HLA
  • Indifférencié
  • Marqueur tumoral
  • Nasopharyngeal
  • Nasopharynx
  • Oncogenes
  • Radiothérapie
  • Sérologie
  • Undifferentiated
  • Virus

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Boussen, H., Bouaouina, N., Mokni-Baizig, N., Gamoudi, A., Chouchane, L., Benna, F., & Ladgham, A. (2005). Les carcinomes du nasopharynx: Données actuelles. Pathologie Biologie, 53(1), 45-51. https://doi.org/10.1016/j.patbio.2004.01.006

Les carcinomes du nasopharynx : Données actuelles. / Boussen, H.; Bouaouina, N.; Mokni-Baizig, N.; Gamoudi, A.; Chouchane, Lotfi; Benna, F.; Ladgham, A.

In: Pathologie Biologie, Vol. 53, No. 1, 01.2005, p. 45-51.

Research output: Contribution to journalReview article

Boussen, H, Bouaouina, N, Mokni-Baizig, N, Gamoudi, A, Chouchane, L, Benna, F & Ladgham, A 2005, 'Les carcinomes du nasopharynx: Données actuelles', Pathologie Biologie, vol. 53, no. 1, pp. 45-51. https://doi.org/10.1016/j.patbio.2004.01.006
Boussen H, Bouaouina N, Mokni-Baizig N, Gamoudi A, Chouchane L, Benna F et al. Les carcinomes du nasopharynx: Données actuelles. Pathologie Biologie. 2005 Jan;53(1):45-51. https://doi.org/10.1016/j.patbio.2004.01.006
Boussen, H. ; Bouaouina, N. ; Mokni-Baizig, N. ; Gamoudi, A. ; Chouchane, Lotfi ; Benna, F. ; Ladgham, A. / Les carcinomes du nasopharynx : Données actuelles. In: Pathologie Biologie. 2005 ; Vol. 53, No. 1. pp. 45-51.
@article{20a6c8f33bed47e5a5a1e506f2136d34,
title = "Les carcinomes du nasopharynx: Donn{\'e}es actuelles",
abstract = "Nasopharyngeal carcinoma (NPC) represents an interesting model in the field of head and neck cancers. This cancer is rare in occidental countries (<1/100,000) and relatively moderate to highly frequent in the Mediterranean area and south-east Asia. This disease is linked to Epstein-Barr virus with a latent infection starting in the oropharyngeal epithelium and involving not only both epithelial tumor cells but also B lymphocytes. This viral infection represents the early phase of carcinogenesis where Latent Membrane Protein-1 has an important role via the terminal part of the BARF-1 gene. There are also various chromosomal alterations reported in NPC concerning the regions of chromosomes 3p, 9p, 11q, 13q, 14q et 16q detected essentially in areas of suppressors genes. Allelic and antigenic specificities of class II and II HLA seems to be associated to an increased risk of NPC different according to the incidence areas. Anti-EBV serology is suggestive of for NPC with an elevated level of IgA EA (early antigen) and VCA (viral capsid antigen). Cyfra 21 represents a promising serum marker for NPC with a 80{\%} sensitivity. Radiotherapy remains the base of loco-regional treatment with a more frequent and systematic use of systemic chemotherapy (primary or concomitant) for high-risk-patients (T3-4 and N2-3 disease).",
keywords = "Carcinoma, Carcinome, Chimioth{\'e}rapie, Epstein-Barr, Epstein-Barr virus, G{\`e}ne suppresseur, HLA, Indiff{\'e}renci{\'e}, Marqueur tumoral, Nasopharyngeal, Nasopharynx, Oncogenes, Radioth{\'e}rapie, S{\'e}rologie, Undifferentiated, Virus",
author = "H. Boussen and N. Bouaouina and N. Mokni-Baizig and A. Gamoudi and Lotfi Chouchane and F. Benna and A. Ladgham",
year = "2005",
month = "1",
doi = "10.1016/j.patbio.2004.01.006",
language = "French",
volume = "53",
pages = "45--51",
journal = "Current Research in Translational Medicine",
issn = "2452-3186",
publisher = "Elsevier Masson",
number = "1",

}

TY - JOUR

T1 - Les carcinomes du nasopharynx

T2 - Données actuelles

AU - Boussen, H.

AU - Bouaouina, N.

AU - Mokni-Baizig, N.

AU - Gamoudi, A.

AU - Chouchane, Lotfi

AU - Benna, F.

AU - Ladgham, A.

PY - 2005/1

Y1 - 2005/1

N2 - Nasopharyngeal carcinoma (NPC) represents an interesting model in the field of head and neck cancers. This cancer is rare in occidental countries (<1/100,000) and relatively moderate to highly frequent in the Mediterranean area and south-east Asia. This disease is linked to Epstein-Barr virus with a latent infection starting in the oropharyngeal epithelium and involving not only both epithelial tumor cells but also B lymphocytes. This viral infection represents the early phase of carcinogenesis where Latent Membrane Protein-1 has an important role via the terminal part of the BARF-1 gene. There are also various chromosomal alterations reported in NPC concerning the regions of chromosomes 3p, 9p, 11q, 13q, 14q et 16q detected essentially in areas of suppressors genes. Allelic and antigenic specificities of class II and II HLA seems to be associated to an increased risk of NPC different according to the incidence areas. Anti-EBV serology is suggestive of for NPC with an elevated level of IgA EA (early antigen) and VCA (viral capsid antigen). Cyfra 21 represents a promising serum marker for NPC with a 80% sensitivity. Radiotherapy remains the base of loco-regional treatment with a more frequent and systematic use of systemic chemotherapy (primary or concomitant) for high-risk-patients (T3-4 and N2-3 disease).

AB - Nasopharyngeal carcinoma (NPC) represents an interesting model in the field of head and neck cancers. This cancer is rare in occidental countries (<1/100,000) and relatively moderate to highly frequent in the Mediterranean area and south-east Asia. This disease is linked to Epstein-Barr virus with a latent infection starting in the oropharyngeal epithelium and involving not only both epithelial tumor cells but also B lymphocytes. This viral infection represents the early phase of carcinogenesis where Latent Membrane Protein-1 has an important role via the terminal part of the BARF-1 gene. There are also various chromosomal alterations reported in NPC concerning the regions of chromosomes 3p, 9p, 11q, 13q, 14q et 16q detected essentially in areas of suppressors genes. Allelic and antigenic specificities of class II and II HLA seems to be associated to an increased risk of NPC different according to the incidence areas. Anti-EBV serology is suggestive of for NPC with an elevated level of IgA EA (early antigen) and VCA (viral capsid antigen). Cyfra 21 represents a promising serum marker for NPC with a 80% sensitivity. Radiotherapy remains the base of loco-regional treatment with a more frequent and systematic use of systemic chemotherapy (primary or concomitant) for high-risk-patients (T3-4 and N2-3 disease).

KW - Carcinoma

KW - Carcinome

KW - Chimiothérapie

KW - Epstein-Barr

KW - Epstein-Barr virus

KW - Gène suppresseur

KW - HLA

KW - Indifférencié

KW - Marqueur tumoral

KW - Nasopharyngeal

KW - Nasopharynx

KW - Oncogenes

KW - Radiothérapie

KW - Sérologie

KW - Undifferentiated

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=11144348674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144348674&partnerID=8YFLogxK

U2 - 10.1016/j.patbio.2004.01.006

DO - 10.1016/j.patbio.2004.01.006

M3 - Review article

VL - 53

SP - 45

EP - 51

JO - Current Research in Translational Medicine

JF - Current Research in Translational Medicine

SN - 2452-3186

IS - 1

ER -